Pembrolizumab

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.

Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin (pruritus), diarrhea, nausea, rash, fever (pyrexia), cough, difficulty breathing (dyspnea), constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It works by targeting the cellular pathway of proteins found on the body's immune cells and some cancer cells, known as PD-1/PD-L1.

Pembrolizumab was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability). It is on the World Health Organization's List of Essential Medicines.

Contents

Medical uses

Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain

As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line t... ...read more

Cancer immunotherapy
5 months ago

Cancer immunotherapy ... checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab. Dendritic cell therapy provokes anti-tumor responses by causing dendritic...

PD-1 and PD-L1 inhibitors
3 months ago

PD-1 and PD-L1 inhibitors ... immunotherapy drugs blocking LAG3, B7-H3, KIR, OX40, PARP, CD27, and ICOS. Pembrolizumab (formerly MK-3475 or lambrolizumab, Keytruda) was developed by Merck...

Non-small-cell lung carcinoma
5 months ago

Non-small-cell lung carcinoma ... system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody...

Bladder cancer
5 months ago

Bladder cancer ... pembrolizumab may have only minimal effects on the rate of death resulting from treatment or the rate at which the cancer advances. Pembrolizumab may...

Monoclonal antibody
5 months ago

Monoclonal antibody ... Bevacizumab Cetuximab Gemtuzumab ozogamicin Ipilimumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal antibodies used for autoimmune...

Melanoma
6 months ago

Melanoma ... often costly. For example, one immune check point inhibitor treatment, pembrolizumab, costs $10,000 to US$12,000 for a single dose administered every 3 weeks...

Incyte
3 months ago

Incyte ... development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo). In 2014, Incyte...

Treatment of lung cancer
5 months ago

Treatment of lung cancer ... treatment options. Pembrolizumab monotherapy is an appealing approach for these patients, with median OS of 30 months with pembrolizumab single agent compared...

Jimmy Carter
5 months ago

Jimmy Carter ... liver, and that he had begun treatment with the immunotherapy drug pembrolizumab and was about to start radiation therapy. His healthcare is being managed...

Checkpoint inhibitor
4 months ago

Checkpoint inhibitor ... cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by...

Merck & Co.
4 months ago
Head and neck cancer
4 months ago
WHO Model List of Essential Medicines
4 months ago
Larotrectinib
5 months ago
List of drugs granted breakthrough therapy designation
3 months ago
Soft-tissue sarcoma
5 months ago
Targeted therapy
4 months ago
Epacadostat
5 months ago
Pemetrexed
5 months ago
This article is copied from an article on Wikipedia® - the free encyclopedia created and edited by its online user community. This article is distributed under the terms of GNU Free Documentation License.